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Lafora disease (LD) is a fatal adolescence-onset neurodegenerative condition. The hallmark of LD is the 
accumulation of aberrant glycogen aggregates called Lafora bodies (LBs) in the brain and other tissues. Impeding 
glycogen synthesis from early embryonic stages by genetic suppression of glycogen synthase (MGS) in an animal 
model of LD prevents LB formation and ultimately the pathological manifestations of LD thereby indicating that 
LBs are responsible for the pathophysiology of the disease. However, it is not clear whether eliminating glycogen 
synthesis in an adult animal after LBs have already formed would halt or reverse the progression of LD. 
Herein we generated a mouse model of LD with inducible MGS suppression. We evaluated the effect of MGS 
suppression at different time points on LB accumulation as well as on the appearance of neuroinflammation, a 
pathologic trait of LD models. 
In the skeletal muscle, MGS suppression in adult LD mice blocked the formation of new LBs and reduced the 
number of glycogen aggregates. In the brain, early but not late MGS suppression halted the accumulation of LBs. 
However, the neuroinflammatory response was still present, as shown by the levels of reactive astrocytes, 
microglia and inflammatory cytokines. 
Our results confirm that MGS as a promising therapeutic target for LD and highlight the importance of an early 
diagnosis for effective treatment of the disease.   
1. Introduction 
Lafora disease (LD; EPM2, OMIM254780) is a fatal adolescence onset 
epilepsy. It is a recessive inherited disease caused by mutations in either 
Epm2a, which encodes laforin, a dual phosphatase with a carbohydrate 
binding domain, or Epm2b, which encodes malin, a ubiquitin E3 ligase 
(Nitschke et al. 2018; Verhalen et al. 2018). Laforin and malin form a 
functional complex that regulates glycogen metabolism (Gentry et al. 
2005; Vilchez et al. 2007), although their mechanism of action and how 
their demise contributes to the accumulation of glycogen in LD remain 
to be elucidated. LD is characterized by the presence of large deposits of 
poorly branched glycogen known as Lafora bodies (LBs) (Chan et al. 
2005; Delgado-Escueta 2007; Ganesh et al. 2006). Two types of LBs have 
been identified in the brain, namely those located in the somas of neu-
rons (neuronal LBs, nLBs) and those amassed in astrocytic processes 
(corpora amylacea-like, CAL) (Auge et al. 2018; Rubio-Villena et al. 
2018). LBs accumulate not only in the brain but also in other tissues, 
such as skeletal muscle and heart (Brewer and Gentry 2019; Cavanagh 
1999). These deposits mainly comprise aberrant, poorly branched 
glycogen, although they also contain proteins related to glycogen 
metabolism that can be used to detect the presence of these aggregates 
and proteins related to the autophagy machinery (Auge et al. 2018; 
Criado et al. 2012; Duran et al. 2014; Puri et al. 2011). 
In the central nervous system (CNS), glycogen is synthesized by the 
muscle isoform of glycogen synthase (MGS). We and others have 
demonstrated that brain LBs underlie the pathophysiology of LD (Duran 
et al. 2014; Pederson et al. 2013; Turnbull et al. 2011a). In our previous 
work, we showed that knocking out the MGS gene (Gys1) from the CNS 
in early embryonic stages in a mouse model of LD (malinKO mice) pre-
vented the formation of LBs and the progression of the disease (Duran 
et al. 2014). Interestingly, the depletion of only one allele of Gys1 in the 
malinKO mice was sufficient to ameliorate the phenotype of this LD 
model. These results identified MGS as a promising therapeutic target 
for LD. In this regard, efforts are being undertaken by several groups to 
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develop molecular tools that could be used as therapeutic agents to 
target MGS in the brain, e.g. by blocking its expression by means of 
antisense oligonucleotides or by reducing its activity using small mo-
lecular weight inhibitors (Solmesky et al. 2017; Tang et al. 2020). Given 
that LD is normally diagnosed after the appearance of clinical symptoms, 
a targeted therapy will necessarily start at a time at which LB tissue 
content is already high. However, there is no information about the 
consequences of targeting MGS expression or activity in adult brains that 
have already developed LBs. To address this point, we generated a 
malinKO mouse in which the deletion of MGS can be induced at any time 
point. Our results demonstrate that in muscle this intervention not only 
blocks the formation of new LBs, but reduces the number of glycogen 
aggregates. In the brain, only with an early intervention, it is possible to 
arrest the amassing of LBs and restore to normal levels proteins that are 
accumulated in the brains of LD models. However, preexisting brain LBs 
are not eliminated and MGS suppression is insufficient to prevent the 
neuroinflammatory response, characteristic of the model. 
2. Materials and methods 
2.1. Animals 
All procedures were approved by the Barcelona Science Park’s Ani-
mal Experimentation Committee and were carried out following Spanish 
(BOE 34/11370–421, 2013) and European Union (2010/63/EU) regu-
lations, and The National Institutes of Health guidelines for the care and 
use of laboratory animals. Mice were maintained in collective cages (up 
to five animals per cage) on a 12/12 h light/dark cycle under specific 
pathogen-free conditions in the Animal Research Center at the Barcelona 
Science Park. Animals were allowed access ad libitum to commercial 
mouse chow and water. After weaning at 3 weeks of age, tail clippings 
were taken for genotyping by qPCR (performed by Transnetyx). Exper-
iments were carried out in C57/Bl6 mice at different ages, the youngest 
at 4 months and the oldest at 11 months. For the generation of malinKO 
with inducible supression of MGS, we combined our MGS conditional 
knockout, based on the Cre-lox technology as described (Duran et al. 
2014) with CreERT2 Cre transgenic mice (B6.129-Gt(ROSA)26Sortm1 
(Cre/ERT2)Tyj/J, Jackson mice), which ubiquitously express a tamoxifen- 
inducible Cre-recombinase. We then combined these mice with 
malinKO mice (Valles-Ortega et al. 2011). Genotyping of the alleles 
involved was performed using specific probes designed and applied by 
TransnetYX®. All experimental protocols were approved by the Barce-
lona Science Park Animal Experimentation Committee, and were carried 
out following Spanish (BOE 34/11370–421, 2013) and European Union 
(2010/63/EU) regulations, and The National Institutes of Health 
guidelines for the care and use of laboratory animals. Experiments were 
conducted using littermates and both males and females were included 
in each group. Where necessary, experimental groups included multiple 
litters for statistical power. 
2.2. Tamoxifen administration 
Tamoxifen solution was prepared fresh each time. To prepare the 
stock at 20 mg/ml, tamoxifen was first dissolved in 100% EtOH, then 
completed with filtered Sunflower seed oil (Sigma) and left overnight 
with agitation at 37 ◦C. A total of three doses of 0.225 mg tamoxifen/g of 
body weight were administered by intraperitoneal injection (IP) in each 
mouse in alternate days. 
2.3. Histology 
Animals were deeply anesthetized with thiobarbital (Braun) and 
perfused transcardially with 4% paraformaldehyde in phosphate buffer 
saline (PBS). Brains and skeletal muscles (quadriceps) were removed, 
postfixed overnight, transversally trimmed, and embedded in paraffin. 
Paraffin sections (3 μm thick) were cut using a Leica microtome. 
Periodic acid-Schiff staining (PAS) was performed using an Artisanlink 
Pro machine (DAKO AR165 kit). For immunofluroescence, the staining 
protocol was optimized and adapted for the requirements of each anti-
body. The primary antibodies used were: anti-MGS (3886, Cell 
signaling); anti-laforin (mouse monoclonal, clon Ab2, gift from Dr. 
Santiago Rodriguez de Córdoba); anti-GFAP (MAB360, Merck Milli-
pore); and anti-Iba1 (019–19,741, Wako-Chem). The secondary anti-
bodies used were: anti-rabbit DyLight 594 (DI-1094, Vector); anti- 
Rabbit Alexa Fluor 488 (A11034, ThermoFisher); anti-Mouse Alexa 
Fluor 568 (A11031, Invitrogen); or/and anti-mouse IgG Alexa Fluor 488 
(405,319, Biolegend), in combination with DAPI (Sigma). The samples 
were mounted in fluorescence mounting media (Dako). For brightfield 
labelling the antibody used was anti-CD11b (ab133357, Abcam) and the 
secondary antibody BrightVision poly HRP-Anti-Rabbit IgG (DPVR- 
110HRP, ImmunoLogic). Antigen–antibody complexes were reveled 
with 3–3′-diaminobenzidine (K346811, Agilent). Sections were coun-
terstained with hematoxylin (CS700, Dako, Agilent) and mounted with 
toluene-free mounting medium (CS705, Agilent). For each case, speci-
ficity of staining was confirmed by staining with a mouse IgG1, Kappa 
(MAB0042 R&D Systems, Biotechne) or a rabbit IgG (ab27478, Abcam) 
isotype control. For the brain, serial sections containing the CA1-CA2- 
CA3 and Dentate gyrus (DG) regions of the hippocampus were 
analyzed. At least 3 sections were analyzed for each sample and staining, 
the number of mice per experimental group is indicated in each figure. 
Brightfield and fluorescent images were acquired with a NanoZoomer- 
2.0 HT C9600 digital scanner (Hamamatsu) equipped with a 20×
objective. All images were visualized with a gamma correction set at 1 
for fluorescence in the image control panel of the NDP.view 2 U12388- 
01 software (Hamamatsu, Photonics, France). Brightness was adjusted 
to improve printing quality to 130% in each colour channel and image. 
The stainings were analyzed by the digital software analysis QuPath 
(Bankhead et al. 2017). For nLBs detection, particle identification was 
stablished to 2–200 μm2 background radius and 0.8–1 circularity for 
nLBs. CAL was defined as the substraction of the number of nLBs from 
the total of particles detected per region. C̈ell detection̈ tool was used to 
detect aggregates, and to detect Iba1-positive cells. ̈ Intensity features̈
was used to calculate pixel intensity/mm2 of the total hippocampal area 
(ROI) in each section for GFAP and CD11b stainings. 
2.4. Glycogen quantification 
Mice were deeply anesthetized with thiobarbital and decapitated. 
The brain and quadriceps were quickly removed and immediately frozen 
in liquid nitrogen. Whole brains and quadriceps were pulverized in 
liquid nitrogen and stored at − 80 ◦C. Frozen brain and muscle aliquots 
were boiled in 30% KOH for 15 min. Glycogen was precipitated in EtOH 
66% and determined by an amyloglucosidase-based assay, as described 
previously (Chan and Exton 1976). 
2.5. Western blot 
Homogenates of frozen tissues were obtained using the following 
buffer: 25 mM Tris-HCl (pH 7.4), 25 mM NaCl, 1% Triton X-100, 0.1% 
SDS, 0.5 mM EGTA, 10 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 10 mM NaF, 25 nM okadaic acid and a protease inhibitor 
cocktail tablet (Roche). To obtain the soluble and the insoluble fractions 
of total homogenates, we followed the protocol previously described 
(Valles-Ortega et al. 2011). Briefly, total homogenates were centrifuged 
at 13000g for 15 min at 4 ◦C. The pellet containing the insoluble fraction 
was recovered in the same volume as the supernatant corresponding to 
the soluble fraction. Samples were loaded on 10% acrylamide gels for 
SDS-PAGE and transferred to Immobilon membranes (Millipore). The 
following primary antibodies were used: anti-GS (rabbit, 3886, Cell 
Signaling); anti-laforin (mouse, 3.5.5, kindly provided by Dr. Santiago 
Rodríguez de Córdoba); and anti-p62 (guinea pig, Progen). The 
following secondary antibodies were used: anti-rabbit and anti-mouse 
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IgG-HRP (GE Healthcare); and anti-guinea pig HRP (Jackson Immuno 
Research). Proteins were detected by the ECL method (Immobilon 
Western Chemiluminescent HRP Substrate, Millipore), and loading 
control of the western blot membrane was performed using the REVERT 
(LI-COR Bioscience) total protein stain. 
2.6. Quantitative (q)PCR 
Total RNA was isolated from frozen brain or quadricep muscle using 
Trizol reagent (LifeTechnologies, Carlsbad, CA, USA). It was then puri-
fied with an RNeasy Mini Kit (Qiagen, Hilden, Germany) and treated 
with DNase I (Qiagen) to degrade genomic DNA. Reverse transcription 
was performed using the qScript cDNA Synthesis Kit (Quanta Bio-
sciences, Beverly, MA, USA). qPCR was performed using a Quantstudio 6 
Flex (Applied Biosystems, Foster City, CA, USA). The following mouse- 
specific SYBRgreen set of primers (Sigma, Madrid, Spain) was used: 
Gys1(forward:CAGAGCAAAGCACGAATCCA,reverse:CATAGCGGCCAG 
CGATAAAG);beta-2microglobulin(b2M),used as a housekeeping gene 
(forward: ATGCACGCAGAAAGAAATAGCAA,reverse:AGCTATCTAG-
GATATTTCCAATTTTTGAA), 18S rRNA housekeeping gene (forward: 
ATTAAGTCCCTGCCCTTTGTACAC, reverse: TAGATAGTCAAGTTCG 
ACCGTCTTCTC),Il6(forward:TAGTCCTTCCTACCCCAATTTCC,reverse: 
TTGGTCCTTAGCCACTCCTTC),CD11b(forward:CCTTGTTCTCTTTGAT 
GCAG,reverse: GTGATGACAACTAGGATCTT), Cxcl10 (forward: 
CCGTCATTTTCTGCCTCATC, reverse:CTCGCAGGGATGATTTCAAG), 
Arginase1(Arg1)(forward:CAGAAGAATGGAAGAGTCAG, reverse: CAG 
ATATGCAGGGAGTCACC). All the samples were run as triplicates. For 
representation of the results, relative expression (2-ΔΔCt) was calculated. 
2.7. Statistics 
Significance between two variables was analyzed using Student’s t- 
test performed with the GraphPad Prism software (La Jolla, CA, USA). 
When indicated, Student’s t-test was validated by linear mixed models 
as follows for internal confirmation. For validation, in cases where the 
quantifications were ratios of continuous variables that are restricted 
between zero and one, beta regression models were considered. Other-
wise, Gaussian errors were assumed after appropriate transformation. 
(a) MGS number or particles in Hp and Cx, laforin number of particles in 
Hp and Cx, CAL and nLBs number in Hp and Cx, GFAP pixel intensity in 
HP and Iba1 cell number in Hp. Measures were log transformed after 
adding a base count of 0.5 to avoid zero misspecifications. Normality 
was assumed after data transformation. Linear mixed effect models were 
fitted using the R package lmerTest (Kuznetsova et al. 2017) including 
the group as variable of interest and the biological replicate as random 
effect. Adjustment for multiple testing (single-step correction method) 
was performed using the R package multcomp (Hothorn et al. 2008). (b) 
Hp_CD11b. For each individual, the repeated measurements were 
averaged out. A Beta regression model, logit link function, was fitted 
using the R package betareg (Cribari-Neto and Zeileis 2010). Adjustment 
for multiple testing (single-step correction method) is performed using 
the R package multcomp. The following p values were considered to be 
statistically significant: p value≤0.05(*), p value ≤0.01 (**), and p value 
≤0.001 (***). 
3. Results 
3.1. Generation of malinKO mice with inducible deletion of MGS 
To obtain animals in which MGS deletion can be induced at a certain 
time point, we combined our conditional MGS knockout, based on the 
Cre-lox technology (Duran et al. 2013), with UBC-Cre-ERT2 mice, in 
which a tamoxifen-inducible Cre recombinase is expressed ubiquitously 
(Ruzankina et al. 2007) thus generating an inducible MGS knockout 
(MGS-KO). We also obtained heterozygous mice for conditional MGS 
(MGS-HET), in which only one of the alleles of MGS is conditional and 
thus can be deleted by Cre recombinase. We then combined MGS-KO and 
MGS-HET mice with malinKO mice, a model of LD that accumulates LBs 
Fig. 1. Experimental groups, timeline and MGS mRNA expression 
levels after tamoxifen administration. A. Control and malinKO mice 
were injected with tamoxifen at either 4 or 6 months of age. Samples 
were collected at the different time points indicated. B. quadriceps 
muscle and brain tissue obtained from 11-month-old wt, malinKO and 
4mMGS-KO + malinKO mice -treated with tamoxifen at 4 months of age. 
Graphics show the MGS mRNA relative expression level (2-ΔΔCt). 18S 
rRNA was used as housekeeping gene for internal control. Each dot 
represents one mouse, n: 5–8. Data are shown as mean ± SD. Statistics: 
Student’s t-test: *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001.   
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and presents astrogliosis and inflammatory response at 11 months 
(Duran et al. 2014) (see Methods and Fig. 1A). We induced MGS 
recombination by IP tamoxifen injection at two points of LD progression: 
1) at 4 months of age (group named 4mMGS-KO + malinKO), a time point 
at which a significant number of LBs have already accumulated in the 
brain and LB-containing fibers could be detected in the muscle; and 2) at 
6 months of age (group named 6mMGS-KO + malinKO), an intermediate 
stage of the disease. The experimental groups analyzed and the group 
comparisons of interest are indicated in Fig. 1A. Briefly, we focused on 
the following comparisons: 1) Eleven-month-old 4mMGS-KO + malinKO 
mice and 6mMGS-KO + malinKO mice compared to malinKO mice of the 
same age; 2) Eleven-month-old 4mMGS-HET + malinKO mice and 6mMGS- 
HET + malinKO mice compared to malinKO mice of the same age; 3) 
Eleven-month-old 4mMGS-KO + malinKO and 6mMGS-KO + malinKO mice 
compared to 4 or 6 months malinKO, respectively (corresponding to the 
time point when tamoxifen was administered), to study a possible 
reversal of LB content. 
Since the expression of Cre is ubiquitous in our conditional mouse 
colony, we compared the effectiveness of knocking out MGS in the 
skeletal muscle (quadriceps) and in the brain of 4mMGS-KO + malinKO 
mice. The efficiency for the Gys1 gene recombination through tamoxifen 
administration was tissue-dependent with a MGS mRNA suppression of 
98% and 70% in skeletal muscle and brain, respectively (Fig. 1B). 
3.2. Effects of MGS suppression on LBs in muscle 
We first studied the effects of MGS deletion on the skeletal muscle of 
11-month-old 4mMGS-KO + malinKO mice. The presence of LBs was 
visualized by Periodic acid-Schiff (PAS) staining, which specifically 
stains carbohydrates, and by immunofluorescence using anti-MGS 
antibody. MGS and other proteins of glycogen metabolism are strongly 
attached to LBs and can thus be used as LB markers. In malinKO animals, 
the skeletal muscle progressively accumulates LBs in specific fibers 
(Turnbull et al. 2011b). 4-month-old malinKO already showed fibers 
containing PAS-positive aggregates that were smaller and less abundant 
than those present in 11-month-old animals (Fig. 2A). These aggregates 
were also detected by MGS immunofluorescence. Neither PAS- nor MGS- 
positive aggregates were detected in control mice. Interestingly, the 
number of LBs was dramatically reduced in 11-month-old 4mMGS-KO +
malinKO mice (Fig. 2A). 
To further assess the effects of depleting MGS expression, we 
measured the levels of proteins known to be attached to LBs and 
increased in malinKO mice, namely MGS and laforin (DePaoli-Roach 
et al. 2010; Duran et al. 2014; Tagliabracci et al. 2008) in total ho-
mogenates and in the soluble and insoluble fractions, the latter being the 
one that contains LB-associated proteins. Western blot analyses of 
muscle homogenates of 4mMGS-KO + malinKO mice confirmed the 
absence of MGS protein, from both the soluble and the insoluble frac-
tions, (Fig. 2B, C), thereby indicating that degradation of the LB-bound 
(insoluble) MGS had also taken place. Laforin was greatly increased in 
the insoluble fraction of aged malinKO mice. Interestingly, MGS sup-
pression in 4mMGS-KO + malinKO mice prevented the accumulation of 
laforin in the insoluble fraction (Fig. 2B, C). 
Next, we measured total glycogen concentration, which includes 
both normal and aggregated glycogen. As expected, at 11 months, the 
total glycogen levels of muscle in malinKO animals were significantly 
elevated compared to age-matched control mice. 4mMGS-KO + malinKO 
mice presented a decrease in muscle glycogen below the levels found at 
4-month-old malinKO mice (Fig. 2D). 
Taken together, these results show that suppression of MGS expres-
sion in the skeletal muscle of LD mice blocked the formation of new LBs 
and led to a reduction in the number of glycogen aggregates. 
3.3. Effects of MGS suppression on LBs in brain 
The impact of MGS suppression on the brain of 11-month-old 4mMGS- 
KO + malinKO mice was first analyzed by PAS staining. LBs were 
distributed throughout the brain parenchyma, being highly abundant in 
the cortex and hippocampus (Criado et al. 2012; Duran et al. 2014; 
Machado-Salas et al. 2012). After MGS suppression, PAS-positive ag-
gregates were still detectable in these two brain structures in 4mMGS-KO 
+ malinKO mice, although they were significantly less abundant than in 
age-matched malinKO counterparts (Fig. 3A). 
We next measured MGS protein levels in total homogenates and in 
the soluble and insoluble fractions. In 4mMGS-KO + malinKO mice, the 
levels of MGS were reduced with respect to age-matched malinKO mice 
in both total homogenates and the insoluble fractions. The MGS sup-
pression also prevented the accumulation of laforin, which is charac-
teristic of the aged malinKO mice (Fig. 3B, C). 
As LD progresses, components of the autophagic machinery, such as 
p62, colocalize with LBs (Auge et al. 2018; Chambers et al. 2018; Duran 
et al. 2014; Puri et al. 2011), which suggests that this machinery is 
unable to complete degradation through autophagosome formation 
(Sánchez-Martín et al. 2015). Increased levels of p62 were found in total 
homogenates and insoluble fractions of malinKO brains, as previously 
reported (Duran et al. 2014). In contrast, the levels of p62 in 4mMGS-KO 
+ malinKO brain homogenates were similar to those of control animals in 
all fractions, again indicating that the build-up of LBs was reduced 
compared to malinKO mice (Fig. 3B, C). 
We next measured total glycogen levels and observed a 2.7-fold in-
crease in the malinKO brain at 11 months compared to age-matched 
control animals (Fig. 3D). These levels remained elevated in 4mMGS- 
KO + malinKO mice. These results indicated that MGS suppression in 
brain achieved only a partial arrest of glycogen and LBs accumulation, 
and revealed the need for further analysis using quantitative biochem-
ical and imaging methods. 
To further determine the scope of the MGS suppression approach in 
the brain, we used immunofluorescence to analyze two regions of the 
brain, namely the hippocampus (Fig. 4) and cortex (Fig. 5). The total 
number of LBs in these two regions of the brain at each time point was 
determined by anti-MGS antibody staining and anti-laforin antibody 
staining (Fig. 4B, C). Laforin was particularly abundant in nLBs (Fig. 4B) 
and both MGS and laforin staining showed a progressive accumulation 
in 4-, 6- and 11-month-old malinKO mice (Fig. 4A, B, 5A, B). Importantly, 
LB accumulation was arrested at the time point of MGS suppression (4- 
months) in both the hippocampus (Fig. 4B, C) and the cortex (Fig. 5B, C) 
in 4mMGS-KO + malinKO, since the levels of the two LB markers were 
comparable to those of 4-month-old malinKO mice (Fig. 4B, C) and 
clearly lower than in 11-months-old malinKO mice. 
As 4mMGS-KO + malinKO mice showed a clear arrest of LB accumu-
lation, we checked the impact of a later intervention, i.e. after 6 months 
of LD progression (6mMGS-KO + malinKO). In this condition, no differ-
ences in LB accumulation were found with respect to 11-month-old 
malinKO mice in the hippocampus or in the cortex (Fig. 5A, B). 
Fig. 2. MGS suppression in skeletal muscle. A. PAS staining. Representative images of quadriceps muscle stained with PAS (upper panels) and MGS (green) with 
DAPI (blue) (lower panels) for each experimental mouse group. Scale bar: 100 μm. B. MGS and laforin protein detection by western blot from total homogenates and 
soluble and insoluble fractions. Two representative samples for 4-month-old control mice and three representative samples for the other groups are shown in each 
western blot. Loading control: LICOR- revert staining. C. Quantifications of protein detected by western blot. Relative optical density (OD) units were related to 
loading control and normalized to the 4-month-old control group. D. Total glycogen measurement. Total amount of glycogen was determined in quadriceps muscles 
from animals in each experimental group (μg/mg tissue). In all the graphics each dot represents one mouse. Data are shown as mean ± SD. n = 2–7 mice per group as 
indicated. Statistics: Student’s t-test. *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred 
to the web version of this article.) 
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Fig. 3. MGS suppression in the brain. A. PAS staining. Representative images from prefrontal cortical region, Cx (upper panels) and hippocampal region, Hp (lower 
panels) from brains of each experimental group. Scale bar: 100 μm. B. MGS, laforin and p62 protein content in brain. Two representative samples of total ho-
mogenates, and soluble and insoluble fractions for each group is shown. Loading control: LICOR- revert staining. n = 3–6 mice per group. C. Quantifications of 
protein detected by western blot. Relative optical density (OD) units were related to loading control and normalized to the 4-month-old control group. D. Total 
amount of glycogen was determined in brain from animals in each experimental group (μg/mg tissue): 4 and 11-month-old control mice, 4 and 11-month-old malinKO 
mice and 4mMGS-KO + malinKO mice.Statistics: Student’s t-test. *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001. In all the graphics each dot represents one mouse, n = 3–6 mice 
per group as indicated. Data are shown as mean ± SD. Statistics: Student’s t-test. *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001. 
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We next studied 4mMGS-HET + malinKO and 6mMGS-HET + malinKO 
brain samples, in which only one of the MGS alleles is conditional and is 
thus deleted after tamoxifen administration, generating heterozygous 
animals that have a lower expression of MGS than their homozygous 
counterparts (Duran et al. 2014). In these mice, the LB content was 
comparable to that of age-matched malinKO mice (Fig. 4B). Therefore, 
knocking out only one allele of MGS was not enough to arrest LB 
accumulation. 
We next quantified LB subtypes, namely CAL and nLBs, indepen-
dently by means of a digital analysis based on aggregate size and 
Fig. 4. LB quantification in the hippocampal region. A. LB visualization in the hippocampus by immunofluorescence. Representative images of the CA2/CA3 region 
of the hippocampus (Hp) stained with anti-MGS (green, upper panels) and anti-laforin (green, lower panels) antibodies in combination with DAPI (blue) from each 
group. Scale bar: 100 μm. B. Total number of particles detected in the whole Hp area from each brain by anti-MGS and anti-laforin antibodies staining. Mean values 
between experiments are represented, a total of 3–4 non-consecutive sections were measured per brain for MGS staining and 4–6 non-consecutive sections for laforin 
staining. Data are expressed as number of particles per mm2, shown as mean ± SD. C. Quantification of CAL and nLBs in the hippocampus by MGS staining. Data are 
expressed as number of particles per mm2, shown as mean ± SD. 3–4 sections were analyzed in each brain sample from n = 2–9 mice per group as indicated. In all the 
graphics, each dot represents one mouse. Student’s t-test test validated by a linear mixed effect model analysis: *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Fig. 5. LB quantification in the cortical prefrontal region. A. Cortical LB visualization by immunofluorescence. Representative images of the prefrontal cortex region 
(Cx) stained with anti-MGS (green, upper panels) and anti-laforin (green, lower panels) antibodies in combination with DAPI (blue) from each group. Scale bar: 100 
μm. B. Total number of particles detected in Cx from each brain by anti-MGS and anti-laforin antibodies stainings. Mean values between experiments are represented, 
a total of 3–4 non-consecutive sections were measured per brain for MGS and 4–6 non-consecutive sections for laforin. Each dot represents one mouse. Data are 
expressed as number of particles per mm2. C. Quantification of CAL and nLBs in the prefrontal cortex by MGS staining. Mean values between experiments are 
represented 3–4 sections were analyzed in each brain n = 2–10 mice per group as indicated. Data are expressed as number of particles per mm2, shown as mean ± SD. 
In all the graphics, each dot represents one mouse. Statistics: Student’s t-test test validated by by a linear mixed effect model analysis: *p ≤ 0.05, ** p ≤ 0.005, *** p 
≤ 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Fig. 6. Astrogliosis in hippocampus by GFAP immunofluorescence. A. Representative images of the Hp regions of each experimental group stained with anti-GFAP 
antibody (red) and DAPI (blue). Scale bar: 500 μm. B. Quantification of GFAP inmunostaining. The percentage of positive pixel for GFAP staining was quantified and 
represented as % positive pixel/mm2. Mean values between experiments are shown from 3 non-consecutive sections for each sample. Each dot represents one animal, 
n = 5–10. Data are shown as mean ± SD. Statistics: Student’s t-test validated by a linear mixed effect model analysis: *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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morphological parameters (see Methods section). As reflected in the 
quantifications, 4mMGS-KO + malinKO mice showed an arrest in the for-
mation of both CAL and nLBs in the hippocampus (Fig. 4C) and in the 
cortex (Fig. 5C), indicating that the arrest of the accumulation of LBs 
occurred both in neurons and astrocytes. 
3.4. Impact of MGS suppression on neuroinflammation 
Neuroinflammation is one of the most important traits in the path-
ophysiology of LD (Lahuerta et al. 2020). To assess its extent, we 
quantified the presence of reactive astrocytes by immunohistochemistry 
with antibodies against GFAP (Fig. 6), and the activation of microglia 
Fig. 7. Microgliosis in hippocampus by CD11b immunohistochemistry. A. Representative images of the Hp regions of each experimental group stained with anti- 
CD11b. Scale bar: 500 μm. B. Quantification of hippocampal microgliosis with CD11b staining. The percentage of CD11b positive pixels per area was quantified 
and represented as n of CD11b positive cells/mm2. Mean values and SD from serial analysis is shown. Data from 2 to 3 non-consecutive brain sections. Each dot 
represents one mice. Scale bar: 500 μm. Statistics: Student’s t-test test validated by a linear mixed effect model analysis: *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001. 
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through immunostaining with anti-Iba1 (Fig. 7) and anti-CD11b (Fig. 8) 
in the hippocampus of the different groups. A small increase in the 
number of astrocytes was detected in 4-month-old malinKO brains, but 
reactive astrocytes were markedly increased in the hippocampus of 11- 
month-old malinKO mice confirming previous results (Duran et al. 2014) 
(Fig. 6). However, we did not observe a significant reduction in GFAP- 
positive astrocytes in the hippocampus of 4mMGS-KO + malinKO or 
6mMGS-KO + malinKO mice compared to age-matched malinKO mice. 
Similarly, both Iba1- (Fig. 7) and CD11b-positive microglia (Fig. 8) were 
increased in 11-month-old malinKO mice and were statistically indis-
tinguishable from age-matched 4mMGS-KO + malinKO animals. 
An inflammatory response in the brain can be evaluated as well by 
measuring the expression of interleukins or chemokines, namely Il6 and 
Cxcl10, that are normally absent in control mice but are increased in LD 
(Lahuerta et al. 2020; López-González et al. 2017). We also analyzed the 
expression of Arginase-1 (Arg-1) the expression of which is associated 
with a neuroprotective role of microglia (Cheon et al. 2017; Sica et al. 
2015; Tugal et al. 2013) and CD11b for microglial population. Il6, 
Cxcl10 and C11b expression was increased in 11-month-old malinKO 
brains compared to age-matched controls, but expression in 4mMGS-KO 
+ malinKO brains was statistically indistinguishable from malinKO brains 
(Fig. 8C). No differences in Arg-1 expression were found among the 
groups (Fig. 8C). Taken together, these results indicate that an inflam-
matory response persists in the brain of 11-month-old 4mMGS-KO +
malinKO mice despite the arrest of LB accumulation. 
4. Discussion 
The demonstration that LB accumulation underlies the pathophysi-
ology of LD identified MGS as a druggable target for the treatment of the 
disease. However, the question remained as to whether this therapeutic 
approach would be effective once LBs have accumulated. Here we 
demonstrate that it is possible to arrest the progressive accumulation of 
LBs in skeletal muscle and brain by suppressing MGS expression after the 
onset of the disease in adult malinKO mice, although there are important 
differences between the two tissues. 
In skeletal muscle, we found a reduction in the number of LBs as 
revealed by PAS, the prevention of insoluble laforin accumulation, and a 
decrease in soluble and insoluble glycogen levels. On the basis of these 
results, we hypothesize that once glycogen synthesis was arrested in 
muscle, not only the formation of new LBs was prevented, but that some 
of the preexisting LBs were degraded. This LB clearance would occur 
through a yet unknown malin/laforin-independent mechanism. 
In the brain, the accumulation of LBs was arrested upon MGS sup-
pression at 4 months, and by the time the mice reached 11 months of 
age, the number of LBs, and the laforin and p62 protein content were 
similar to those seen at 4 months of age. However, both laforin and p62 
remained detectable in the insoluble fraction, and total glycogen levels 
remained elevated compared to control mice. On the basis of these re-
sults, we conclude that MGS suppression in the brain arrested the 
accumulation of new LBs of both types, CAL and nLBs, but did not 
facilitate the clearance of preexisting LBs. Our results also show that 
suppressing MGS at 6 months of age is far less effective that at 4 months. 
This remarks the importance of an early intervention for a successful 
treatment of the disease. Furthermore, as shown by the results obtained 
in 4mMGS-HET + malinKO and 6mMGS-HET + malinKO mice, knocking out 
only one MGS allele is not effective, indicating that a thorough reduction 
of MGS expression is required to block the progression of the 
accumulation of LBs in the adult brain. Several factors might contribute 
to the differences found between muscle and brain. First, the efficiency 
of Gys1 recombination after tamoxifen induction differs between the 
two tissues, being complete in skeletal muscle but partial in the brain. 
Second, the relative number of LBs in both tissues in 4-month-old mice 
differs, being much more abundant in the brain. Third, there are tissue- 
associated differences in LB characteristics such as size, morphology and 
cellular distribution, which might determine their availability for 
degradation after MGS suppression. Further work is needed to elucidate 
the presence of distinct LB degradation mechanisms across tissues and 
also within the LB types present in the brain (CAL and nLBs). 
In the 4mMGS-KO + malinKO brain, although LB accumulation was 
arrested by MGS suppression and LB-associated proteins were main-
tained at levels that correspond to those of 4-month-old malinKO mice, 
we did not observe an amelioration on the neuroinflammatory response. 
Although these observations might be limited by the partial efficiency of 
MGS suppression in the brain, they underlay importance of the time 
point at which MGS is suppressed. In our malinKO mice, the progression 
of LD from 0 to 6 months was slow but accelerated from 6 to 11 months, 
a period in which neuroinflammation became evident with the specific 
markers used against reactive astrocytes and microglia. However, it has 
been recently described that inflammation can be detected as early as at 
3 months (Lahuerta et al. 2020; López-González et al. 2017). Thus, 
neuroinflammation could already be irreversible in 4-month-old 
malinKO mice. In this context, early intervention becomes essential to 
optimize the effects of MGS suppression. In this regard, the precise time 
at which the first LBs appear in patients and in experimental models of 
LD remains unknown. In patients, LB formation is expected to start 
before the first clinical manifestations, frequently seen during infancy 
and adolescence. In mice, laforin accumulation can be detected at 3- 
month-old malinKO mice and LBs at 3 months (Criado et al. 2012; 
Machado-Salas et al. 2012), thereby opening up the possibility for even 
earlier appearance of these aggregates. 
5. Conclusions 
Our findings show that MGS suppression early after the onset of LD 
arrests the accumulation of LBs in the brain, greatly reduces LB and 
glycogen content in muscle, and reverts alterations of LB-associated 
proteins in brain and muscle. However, MGS suppression in the adult 
brain is insufficient to prevent the appearance of neuroinflammation at 
the time points tested. Thus, the arrest of LB accumulation by MGS 
suppression might contribute to ameliorate the progression of LD only 
when this approach is applied at early stages of the disease. Further-
more, our findings confirm the relevance of the development of mo-
lecular tools targeting MGS to efficiently modify the progression of LD, 
but that in order to be effective they should block a high percentage of 
the MGS expression or activity and the treatment should be imple-
mented as early as possible. Consequently, it is crucial to achieve an 
early genetic diagnosis in LD patients, including asymptomatic sibling-
sin order to initiate any potential LD treatment at a stage with the lowest 
possible accumulation of LBs in the brain. 
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Diabetes y Enfermedades Metabólicas Asociadas (ISCIII, Ministerio de 
Ciencia e Innovación) and a grant from the National Institutes of Health 
(NIH-NINDS) (P01 NS097197) to JJG. None of the supporting agencies 
had any role in establishing the work or in writing the manuscript. 
Declaration of Competing Interest 
None. 
Acknowledgments 
We wish to thank Anna Adrover, Emma Veza, Vanessa Hernandez 
and Laura I. Alcaide for technical assistance, Tanya Yates for correcting 
the English manuscript and the members of the Histopathology, Mouse 
Mutant, Advanced Digital Microscopy and Biostatistics facilities at IRB 
Barcelona for their assistance and Kathryn Brewer for helpful 
discussions. 
References 
Auge, E., Pelegri, C., Manich, G., Cabezon, I., Guinovart, J.J., Duran, J., Vilaplana, J., 
2018. Astrocytes and neurons produce distinct types of polyglucosan bodies in 
Lafora disease. Glia 66, 2094–2107. 
Bankhead, P., Loughrey, M.B., Fernández, J.A., Dombrowski, Y., McArt, D.G., Dunne, P. 
D., McQuaid, S., Gray, R.T., Murray, L.J., Coleman, H.G., James, J.A., Salto- 
Tellez, M., Hamilton, P.W., 2017. QuPath: open source software for digital pathology 
image analysis. Sci. Rep. 7, 017–17204. 
Brewer, M.K., Gentry, M.S., 2019. Brain glycogen structure and its associated proteins: 
past, present and future. Adv Neurobiol 23, 17–81. 
Cavanagh, J.B., 1999. Corpora-amylacea and the family of polyglucosan diseases. Brain 
Res. Brain Res. Rev. 29, 265–295. 
Chambers, J.K., Thongtharb, A., Shiga, T., Azakami, D., Saito, M., Sato, M., 
Morozumi, M., Nakayama, H., Uchida, K., 2018. Accumulation of Laforin and other 
related proteins in canine Lafora disease with EPM2B repeat expansion. Vet. Pathol. 
55, 543–551. 
Chan, T.M., Exton, J.H., 1976. A rapid method for the determination of glycogen content 
and radioactivity in small quantities of tissue or isolated hepatocytes. Anal. Biochem. 
71, 96–105. 
Chan, E.M., Andrade, D.M., Franceschetti, S., Minassian, B., 2005. Progressive 
myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv. Neurol. 95, 47–57. 
Cheon, S.Y., Kim, E.J., Kim, J.M., Kam, E.H., Ko, B.W., Koo, B.N., 2017. Regulation of 
microglia and macrophage polarization via apoptosis signal-regulating kinase 1 
silencing after ischemic/hypoxic injury. Front. Mol. Neurosci. 10. 
Criado, O., Aguado, C., Gayarre, J., Duran-Trio, L., Garcia-Cabrero, A.M., Vernia, S., San 
Millan, B., Heredia, M., Roma-Mateo, C., Mouron, S., Juana-Lopez, L., 
Dominguez, M., Navarro, C., Serratosa, J.M., Sanchez, M., Sanz, P., Bovolenta, P., 
Knecht, E., Rodriguez de Cordoba, S., 2012. Lafora bodies and neurological defects 
in Malin-deficient mice correlate with impaired autophagy. Hum. Mol. Genet. 21, 
1521–1533. 
Cribari-Neto, F., Zeileis, A., 2010. Beta Regression in R. J. Stat. Softw. 1 (2), 2010. 
Delgado-Escueta, A.V., 2007. Advances in lafora progressive myoclonus epilepsy. Curr. 
Neurol. Neurosci. Rep. 7, 428–433. 
DePaoli-Roach, A.A., Tagliabracci, V.S., Segvich, D.M., Meyer, C.M., Irimia, J.M., 
Roach, P.J., 2010. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to 
lafora bodies and the accumulation of insoluble laforin. J. Biol. Chem. 285, 
25372–25381. 
Duran, J., Saez, I., Gruart, A., Guinovart, J.J., Delgado-García, J.M., 2013. Impairment in 
long-term memory formation and learning-dependent synaptic plasticity in mice 
lacking glycogen synthase in the brain. J. Cerebral Blood Flow Metab. Off. J. Int. Soc. 
Cerebral Blood Flow Metab. 33, 550–556. 
Duran, J., Gruart, A., Garcia-Rocha, M., Delgado-Garcia, J.M., Guinovart, J.J., 2014. 
Glycogen accumulation underlies neurodegeneration and autophagy impairment in 
Lafora disease. Hum. Mol. Genet. 23, 3147–3156. 
Ganesh, S., Puri, R., Singh, S., Mittal, S., Dubey, D., 2006. Recent advances in the 
molecular basis of Lafora’s progressive myoclonus epilepsy. J. Hum. Genet. 51, 1–8. 
Gentry, M.S., Worby, C.A., Dixon, J.E., 2005. Insights into Lafora disease: Malin is an E3 
ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. 
Natl. Acad. Sci. U. S. A. 102, 8501–8506. 
Hothorn, T., Bretz, F., Westfall, P., 2008. Simultaneous inference in general parametric 
models. Biom. J. 50, 346–363. 
Kuznetsova, A., Brockhoff, P.B., Christensen, R.H.B., 2017. lmerTest package: tests in 
linear mixed effects models. J. Stat. Softw. 1 (13), 2017. 
Lahuerta, M., Gonzalez, D., Aguado, C., Fathinajafabadi, A., García-Giménez, J.L., 
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